53 completed, 20 unknown, 3 terminated, 2 not yet recruiting. 33 Phase 1, 27 Not applicable, 9 Phase 3, 2 Phase 2, 2 Phase 4.
Follow Test: new trials by email Literature Review of Test trials Research Report on Test
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mentalization and Social Cognition in Adolescents After Suicide Attempt Test, Questionnaires - Violent Suicide Attempts in Adolescents | Not applicable | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 82 | 2026-10-01 | 2026-09-18 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-339 in Healthy Volunteers CKD-339, D311, D107 - Hypertension | Phase 1 | Not yet recruiting | Chong Kun Dang Pharmaceutical | 76 | 2026-08-20 | 2026-08-06 |
| Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery Test, Questionnaires - Neurodevelopmental Disorders, Autism Spectrum Disorder | Not applicable | Recruiting | Assistance Publique - Hôpitaux de Paris | 100 | 2026-04-08 | 2026-04-16 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers CKD-383 0.25/12.5/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-30 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers CKD-383 0.5/10/1000mg, CKD-501, D744, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 30 | 2025-10-28 | 2025-12-26 |
| Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers CKD-383 0.5/25/1000mg, CKD-501, D745, D150 - Type 2 Diabetes | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2025-10-24 | 2025-12-26 |
| Dual Task and Attention Deficit and Hyperactivity Disorder test - Attention Deficit Disorder With Hyperactivity (ADHD) | Completed | Gaziantep Islam Science and Technology University | 60 | 2025-09-01 | 2025-12-12 | |
| Bioequivalence Study of Vortioxetine in 20 mg Coated Tablets in Healthy Subjects Under Fasting Conditions Reference, Test - Bioequivalance | Phase 1 | Completed | ADIUM | 20 | 2025-03-18 | 2026-06-03 |
| Brivaracetam Bioequivalence Assessment Briveka ® 100 mg, Briviact® 100 mg - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Zodiac Produtos Farmaceuticos S.A. | 28 | 2024-08-09 | 2026-09-02 |
| A Study to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UI059 and UIC202201 UI059, UIC202201 - Gastro-Intestinal Disorder | Phase 1 | Unknown | Korea United Pharm. Inc. | 66 | 2024-07-03 | 2024-05-01 |
| Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops - Dry Eye Disease (DED) | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 86 | 2024-03-20 | 2025-07-03 |
| Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft Ibuprofen 600 mg, Placebo, Acetaminophen - Pain, Post Operative, Quality of Life | Phase 4 | Recruiting | Marquette University | 50 | 2023-10-19 | 2024-09-27 |
| A Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of UI059 and UIC202201 in Healthy Subjects UI059, UIC202201 - GERD | Phase 1 | Completed | Korea United Pharm. Inc. | 8 | 2023-10-08 | 2023-11-21 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy | Phase 1 | Completed | Eli Lilly and Company | 57 | 2023-08-29 | 2024-03-29 |
| Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-22 | 2023-09-06 |
| Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50 - Bioequivalence | Phase 1 | Unknown | Respirent Pharmaceuticals Co Ltd. | 34 | 2023-08-01 | 2023-08-31 |
| Implementation of a Program to Strengthen Oral Hygiene in Patient With Cleft Deformities Test - Orofacial Cleft | Not applicable | Completed | Nantes University Hospital | 60 | 2023-05-31 | 2026-09-14 |
| Effect of Ozone Oil After Non-surgical Periodontal Treatment test, Control - Periodontal Diseases | Not applicable | Unknown | Universidade Federal Fluminense | 16 | 2023-04-05 | 2023-06-07 |
| Impact of Full Mouth Erythritol Powder Air Polishing on Systemic Inflammatory Response test, conventional - Periodontal Diseases | Not applicable | Unknown | University of Baghdad | 42 | 2023-03-10 | 2023-04-19 |
| Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets Dapagliflozin 10 mg film-coated tablet, Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia - Healthy | Not applicable | Completed | Dexa Medica Group | 24 | 2023-03-08 | 2023-11-13 |
Showing 20 of 82. Sign in to see all of them.
Asthma (6) · Diabetes Mellitus, Type 2 (3) · Metabolic Diseases (3) · Periodontitis (3) · Arthritis, Rheumatoid (2) · Astigmatism (2) · Attention Deficit Disorder with Hyperactivity (2) · Back Pain (2) · COVID-19 (2) · Cardiovascular Diseases (2) · Dry Eye Syndromes (2) · Gastroesophageal Reflux (2) · Hepatitis B, Chronic (2) · Keratoconjunctivitis Sicca (2) · Osteoarthritis (2)
Chong Kun Dang Pharmaceutical (12) · Respirent Pharmaceuticals Co Ltd. (9) · Johnson & Johnson Vision Care, Inc. (6) · Daewon Pharmaceutical Co., Ltd. (3) · Korea United Pharm. Inc. (3) · Assistance Publique - Hôpitaux de Paris (2) · Dexa Medica Group (2) · Jadran Galenski laboratorij d.d. (2) · Kahramanmaras Sutcu Imam University (2) · ADIUM (1) · Actavis Inc. (1) · Alcon Research (1) · Aurobindo Pharma Ltd (1) · Bausch & Lomb Incorporated (1) · Biocinese (1)
South Korea (22) · United States (17) · Greece (9) · France (4) · Turkey (Türkiye) (4) · Brazil (3) · Switzerland (3) · India (2) · Indonesia (2) · Serbia (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Egypt (1) · Germany (1)
Chrysoula Doxani, MD, MSc, PhD (5) · Amy R Leader, DrPH, MPH (1) · Catherine Grosmaitre, PhD (1) · Chrysoula Doxani, Dr. (1) · Dae-Kyeong Jun, M.D, Ph.D (1) · Daehyeok Kim, M.D, Ph.D (1) · Daein Lee, M.D, Ph.D (1) · Danang A Yunaidi, MD (1)
PMID 25473263, PMID 27445067, PMID 28736342, PMID 28736344, PMID 29021286, PMID 31895273, PMID 38586120, PMID 38771476, PMID 39789639, PMID 41970000, PMID 42235640, PMID 42515774, PMID 42773919, PMID 42837491
2016 (1), P30CA014089 (1), R21DK108076 (1)